Active Surveillance Criteria for Prostate Cancer Amongst Dutch Urologists
Cancer Research Journal
Volume 2, Issue 5, September 2014, Pages: 98-101
Received: Sep. 23, 2014; Accepted: Oct. 8, 2014; Published: Oct. 20, 2014
Views 2163      Downloads 116
Authors
Erwin Hendrik Denies, Department of Urology, Jeroen Bosch ziekenhuis, ‘S Hertogenbosch, The Netherlands
Filip Weckx, Department of Urology, Sint-Franciscusziekenhuis, Heusden-Zolder, Belgium
Rob Schipper, Department of Urology, Jeroen Bosch ziekenhuis, ‘S Hertogenbosch, The Netherlands
Bart Schrier, Department of Urology, Jeroen Bosch ziekenhuis, ‘S Hertogenbosch, The Netherlands
Article Tools
Follow on us
Abstract
Introduction: This survey amongst Dutch urologists aimed to investigate their criteria before enrolling patients to active surveillance (AS) and managing follow-up. Materials and Methods: An online survey was distributed to 421 Dutch urologists. Demographics, enrollment criteria, intervention criteria and the role of magnetic resonance imaging (MRI) in AS were questioned. Results: 15% responded and completed the survey. A major 98% see AS as an alternative treatment for low-risk prostate cancer (PCa). 79% felt that patients with a PSA ≤10 ng/ml were eligible for AS and 74% felt that patients required a Gleason score ≤6 for admitting to AS. There was agreement on the timing of second biopsies but, not for subsequent biopsies. 58% see a role for MRI in AS. Conclusions: Dutch urologists are accepting AS. They were in agreement regarding enrollment criteria, the best time for second biopsy, but there was no agreement on the timing of follow-up biopsies.
Keywords
Active Surveillance, Survey, Watchful Waiting, Prostate Cancer
To cite this article
Erwin Hendrik Denies, Filip Weckx, Rob Schipper, Bart Schrier, Active Surveillance Criteria for Prostate Cancer Amongst Dutch Urologists, Cancer Research Journal. Vol. 2, No. 5, 2014, pp. 98-101. doi: 10.11648/j.crj.20140205.14
References
[1]
Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO et al. The contemporary concpt of significant versus insignificant prostate cancer. Eur Urol 2011; 60: 291 – 303
[2]
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part1: screening, diagnosis and treatment of clinically localised disease. Eur Urol 2011; 59: 61–71
[3]
Gorin MA, Eldefrawy A, Ekwenna O, Soloway MS. Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists. Prostate Cancer and Prostatic Diseases (2012) 15, 177–181
[4]
R.C. van den Bergh, S. Roemeling, M.J. Roobol, et al. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int. 2009;103:1472-1477
[5]
A.V. D’Amico, M.H. Chen, K.A. Roehl, W.J. Catalona, Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135
[6]
A.V. D’Amico, A.A. Renshaw, B. Sussman, M.H. Chen. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447
[7]
Van Den Bergh R. PRIAS: Prostate cancer Research International: Active Surveillance - guideline and study for the expectant management of localized prostate cancer with curative intent. https://www.prias-project.org
[8]
D.M. Latini, S.L. Hart, S.J. Knight, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178:826-831 discussion 831–2
[9]
L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, A. Loblaw. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-131
[10]
M.A. Dall’Era, B.R. Konety, J.E. Cowan, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664-2670
[11]
G. Ploussard, E. Xylinas, X. Durand, et al. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. BJU Int. 2011;108:513-517
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186